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Background: Contrast-induced acute kidney injury is a common cause of iatrogenic acute kidney injury (AKI). Most
of the published estimates of AKI after contrast use originate from the cardiac catheterization literature despite
contrast-enhanced computed tomography (CT) scans being the more common setting for contrast use. This
systematic review aims to summarize the current evidence about (1)the risk of AKI following intravenous (IV)
contrast-enhanced CT scans and(2) the risk of clinical outcomes (i.e. death, hospitalization and need for renal
replacement therapy) due to IV contrast-enhanced CT scans.
Methods/Design: A systematic literature search for published studies will be performed using MEDLINE, EMBASE
and The COCHRANE Library databases. Unpublished studies will be identified by searching through grey literature.
No language restriction will be applied.
The review will consider all studies that have examined the association between IV contrast media and AKI. To be
selected, the study should include two arms: one group of exposed patients who received IV contrast material
before CT scans and one group of unexposed group who did not receive contrast material before CT scans. Two
authors will independently screen titles and abstracts obtained from electronic databases, extract data and will
assess the quality of the studies selected using the Cochrane's ‘Risk of Bias’ assessment tool for randomized trials
and the Newcastle-Ottawa Scale for observational studies. A random-effects meta-analysis will be performed if there
is no remarkable heterogeneity between studies.
Discussion: This systematic review will provide synthesis of current evidence around the effect of IV contrast
material on AKI and other clinical outcomes. Results will be helpful for making evidence-based recommendations
and guidelines for clinical and radiologic settings.
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Contrast-induced acute kidney injury (CI-AKI) is the
third most common cause of acute kidney injury (AKI)
and the leading iatrogenic and thus potentially preventable
cause of AKI [1]. CI-AKI is associated with long-term ad-
verse outcomes including stroke, myocardial infarction,
end-stage renal disease that requires dialysis, and death
[2-6]. The average in-hospital cost of contrast-induced ne-
phropathy is estimated at US$10,345 while the 1-year cost
of treating a patient with CI-AKI is US$11,812 [7].
Some studies suggest that the risk of AKI is lower after
contrast-enhanced computed tomography (CT) scans com-
pared to the risk following arterial cardiac catheterization
[8,9]. However, practice guidelines and most clinicians
do not differentiate between arterial and intravenous
(IV) routes of contrast administration [10,11]. As such,
practice guidelines recommend that the same prophy-
lactic measures (e.g. volume expansion) be taken to pre-
vent CI-AKI regardless of whether the contrast is being
given intra-arterial (IA) or IV [10-13]. Indeed, data re-
garding prevention of AKI when contrast is adminis-
tered by the IV route, such as with a CT scan, is quite
limited [9,14]. Further, the evidence indicating the inde-
pendent effect of IV contrast material on AKI remains
uncertain. To the best of our knowledge, only two sys-
tematic reviews [15,16] synthesized results from studies
on the association between IV contrast administration
and CI-AKI. These two reviews included a total of 13
studies (25,950 patients) conducted between 1985 and
2008 and comparing the incidence of AKI between a
group of patients who received contrast material and a
control group. They concluded no significant difference
in the incidence of AKI between contrast patients and
control group. This conclusion was confirmed by the
meta-analysis performed in one of the two systematic
reviews [15] showing a relative risk of developing an
AKI after IV contrast material of 0.79 [95% confidence
interval (CI) 0.62–1.02, P = 0.07] in patients who re-
ceived intravenous contrast material compared to the
control group.
However, on closer inspection, the conclusion of these
reviews should be regarded with caution because of the
limitations in the methodology of the included studies.
In fact, although substantial heterogeneity between pa-
tients who underwent contrast material and control group
was noted (especially differences in clinical and baseline
characteristics), the controls for potential confounders
have been completely lacking in most studies. For ex-
ample, ten studies out of 13 included in these reviews
failed to adjust for patient-related confounding factors.
Further among studies that performed adjusted analysis
[17-19], only two [17,19] have controlled for the most
factors indicating the status of renal function, i.e. base-
line serum creatinine (SCr) or glomerular filtration rate(GFR) at admission. Additionally, the definition of CI-AKI
as well as the time between the initial SCr determination
(baseline) and the post-scan SCr determination varied
widely between studies. Such limitations of methodology
could result in an overestimation or underestimation of
the effect of IV contrast material associated to the AKI.
More recently, two studies [20,21] used propensity
matching analysis to estimate the effect of IV contrast
material on AKI, a statistical technique with which the
effects of confounding bias can be reduced in observa-
tional studies [22,23]. In fact, this method estimates the
probability of subjects for being exposed to an exposure
factor according to their baseline characteristics and at-
tributes a score to each subject. Subsequently, subjects
in exposed group and those in unexposed group who
have a similar score are matched. Thus, the matching of
subjects with a similar score mimics a randomization as-
signment because the distribution of baseline covariates
will be the same among exposed and unexposed subjects.
In a sample of 20,242 patients, Davenport et al. [20] re-
ported a post-CT AKI odds ratio (OR) of 1.26 (95% CI
1.07–1.49; P = 0.007) in patients with pre-CT SCr levels of
1.5 mg/dL or greater, while McDonald et al. [21] reported
an OR of 0.97 (95% CI 0.81, 1.16; P = 0.76) in 19,651 pa-
tients with a baseline SCr of 1.5–2.0 mg/dL and an OR of
0.91 (95% CI 0.66, 1.24; P = 0.58) in 12,207 patients with a
baseline SCr of 2.0 mg/dL or more.
Given the methodological weaknesses of studies included
in the previous systematic reviews and the discrepant
results reported by new research that used more robust
methods [20,21], an up-to-date systematic review is needed
to determine the current evidence around the effect of
intravenous contrast material on AKI.
The aims of this systematic review will be to summarize
and quantitate (1) the risk of AKI in patients who under-
went intravenous contrast-enhanced CT scans compared
to patients who did not undergo contrast-enhanced proce-
dures and(2) the risk of clinical outcomes (i.e. death,
hospitalization and need for renal replacement therapy)
due to intravenous contrast in patients who underwent
intravenous contrast-enhanced CT scans compared to pa-
tients who did not undergo contrast-enhanced procedures.Methods/Design
Eligibility criteria
Participant/population
This review will consider all studies conducted among
adult patients aged ≥18 years. Studies must include re-
sults of serum creatinine concentration or GFR assessed
prior to and after CT scan. Studies in patients who re-
ceived contrast material by intra-arterial, intracoronary
only or both intravenous and intra-arterial routes will
be excluded.
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The exposure to be considered will be the contrast ma-
terial administered by IV routes.Type of outcomes
The primary outcome of interest will be AKI following
IV contrast-enhanced CT scans. Secondary outcomes will
include death, hospitalization and need for renal replace-
ment therapy.Type of comparison
Patients who underwent IV contrast-enhanced CT scans
will be compared to patients who did not undergo contrast-
enhanced procedures.Types of studies
The review will consider all studies that have examined
the effect of IV contrast material on AKI (randomized
trials and observational studies). To be selected, a study
should include two arms: one group of exposed patients
who received IV contrast material before CT scans and
one group of unexposed group who did not receive con-
trast material before CT scans. The study also has to re-
port one of the outcomes of interest mentioned above.
Systematic reviews and meta-analysis will be excluded,
but the bibliography of any reviews retrieved will be
scanned for relevant citations.Search strategy
The search strategy will be designed to access both
published and unpublished studies.
To identify published studies, we will perform a sys-
tematic literature search using electronic bibliographic
databases: Medline, Embase and The Cochrane Library.
An adapted search strategy will be used to search all
the databases from their start date up to the date the
search is run. The search terms will be adapted for the
different databases using a combination of Medical Sub-
ject Heading (MeSH) and relevant keywords contained
in titles and abstracts. An information scientist will help
in developing and conducting the search strategy. We
will update the literature search until the draft manu-
script is submitted for peer review. Articles identified
will be downloaded and imported directly in Endnote.
Additional studies will be identified by reviewing the biblio-
graphic reference lists of studies selected from electronic
databases and from relevant systematic reviews.
To identify unpublished studies, we will search through
grey literature including reports and conference abstract
books.
To reduce language bias, we will consider articles
published in any language.Study selection and data extraction
To select studies of interest, at least two authors (from
JFK, SH and AA) will independently screen titles and
abstracts obtained from electronic databases and will
exclude irrelevant articles. A data extraction tool will be
developed based on the Cochrane Consumers and Com-
munication Review Group's data template [24].
Pre-specified data elements from each selected study
will be recorded including study authors, year of study,
year of data collection, country, study design, patient
characteristics and setting (e.g. stroke, trauma), data on
AKI (definition, pre- and post-scan creatinine concentra-
tion, time collection of post-scan creatinine concentration),
data on contrast material (type and volume of contrast),
prophylactic measures, confounding variables included in
the analysis (such as age, sex, comorbidities), sample size
in exposed and control patients, measures of primary out-
come and secondary outcome (incidence rate, odds ratio,
hazard ratio), statistical tests carried out, significance
(P values), precision (confidence intervals) and other
important variables.
JFK and SH will extract and compare the data from
the selected studies. Disagreements between JFK and SH
will be resolved by consensus. A third author (AA) will
review all extracted data. Disagreements between JFK,
SH and AA will be resolved by consensus. If consensus
cannot be reached between the three reviewers, another
investigator (GK) will make the final decision.
Quality assessment
The goal of this assessment is to make a methodological
judgement of whether the design and conduct of the
study compromised the validity of the association be-
tween exposure (IV contrast material) and the outcome
(AKI or other clinical outcomes).
The study quality and the presence of potential bias
within studies will be assessed independently by two au-
thors (JFK and SH) using the Cochrane's ‘Risk of Bias’
assessment tool for randomized studies [25] and the
Newcastle-Ottawa Scale for observational studies [26].
Data synthesis and analysis
If there is no heterogeneity according to the quality of
methods and bias assessment between studies selected,
we will pool results of all comparables studies into a
meta-analysis using the Comprehensive Meta-analysis
software (version 2.2.046, Biostat Inc., Englewood, NJ,
USA). Risk ratios and their 95% CI will be calculated
from the data generated by each included study. To test
heterogeneity of the effect of IV contrast material on the
risk of development of AKI and other clinical outcomes
reported by different studies, we will use Cochran's Q
statistic test (P value <0.1 is considered significant) and
the I2 statistic. The overall effects for the outcomes and
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random-effects model as described by DerSimonian and
Laird [27].
Sensitivity and multivariate meta-regression analyses
will be performed to assess the effects of some clinical
factors and methodological quality of studies on the
meta-analyses estimates. Sensitivity analyses could be
those excluding studies with lower methodological
quality or those published only as abstracts, while co-
morbidities (i.e. baseline kidney function, diabetes) will
be used as covariates for meta-regression.
We will perform subgroup analyses using reported data
on subgroups of patients with underlying chronic kidney
disease. A funnel plot will be used to assess for the pres-
ence of publication and other reporting biases, and a vis-
ual examination of the funnel plot and the Egger's statistic
will be used to test for bias.
If it is not possible to conduct meta-analysis because
of the heterogeneity of studies, a narrative analysis will
be carried out describing the characteristics and quality
of studies included as well as explaining the relationship
between IV contrast material and AKI (size, direction
and consistency of effect).
Discussion
In recent years several meta-analyses addressed the ques-
tion of nephropathy following intravascular contrast ma-
terial [28-31]. These meta-analyses included both IA and
IV studies that were interested either in measuring the in-
cidence and risk factors of CI-AKI in patients undergoing
intravascular contrast material [30,31] or in comparing
different CI-AKI prevention methods/different types of
contrast media (iso-osmolar and low-osmolar contrast) on
risk of CI-AKI [28,29]. However, the IV studies included
in three [28,29,31] of the four meta-analyses were con-
ducted exclusively in patients who received contrast ma-
terial. None included a study comparing patients exposed
to IV contrast material to control group of patients who
did not receive contrast media. Only the meta-analysis
published by Moos et al. included four studies [32-35]
(out of 42 included in the meta-analysis) that included a
control group of patients who were not exposed to IV
contrast material. However, it is not possible to estimate
the average effect of IV contrast material on CI-AKI from
the estimates reported by these four studies because they
were pooled together with estimates reported by other
studies that have not include a control group of patients.
Thus, none of the above meta-analyses have examined
the causal effect of IV contrast material exposure on
CI-AKI, while debates and differences of opinions exist
on the nephrotoxic potential of contrast material when
administered by IV route [36-39]. Moreover, in certain
clinical setting (i.e. cardiac angiography), the risk of intra-
arterial contrast material to kidney function is extrapolatedto intravenous material without consideration of the
evidence [16,36].
Until now, only two systematic reviews [15,16] have
synthesized evidence from 13 studies conducted between
1985 and 2008 that compared the risk of AKI between a
population of patients who received a contrast material
by IV and an unexposed population of patients who did
not receive the contrast material. They reported a simi-
lar risk of AKI between both populations (contrast ex-
posed patients and unexposed patients). However, this
conclusion could be limited by the methodological weak-
nesses used in studies included in these systematic reviews,
especially the lack of control of potential confounding fac-
tors and a selection bias resulting from the selection of
the control group. In particular, two important methodo-
logical limits should be cited. First, we noted that in nine
out of 13 studies included in the more recent review [15],
the mean baseline SCr was higher among unexposed
group than in IV-contrast-exposed group, suggesting a se-
lection bias (higher risk patients did not receive contrast).
Second, the authors of this systematic review reported
having modified the scale assessing the methodological
quality. They excluded the question assessing if the out-
come of interest was not present at the start of the study,
because the researchers did not determine whether pa-
tients had preexisting AKI in any studies included in the
systematic review. These limitations could have affected
the validity of the association between IV contrast and
AKI. In fact, on one hand, to attribute the risk of AKI to
IV contrast exposure, it supposes the absence of AKI cases
in the two groups under study before the exposure. On
another hand, the validity of causal relation between IV
contrast material and AKI depends upon the comparabil-
ity of exposed and unexposed patients.
Since 2008 (date on which the last study included in the
more recent systematic review was published), several
other studies measuring the effect of IV contrast medium
on renal function were published [20,21,34,40-47]. Three
among them [20,21,41] used propensity matching methods
guaranteeing that the group exposed to IV contrast mater-
ial and unexposed group had similar baseline characteris-
tics and had a same likelihood of being exposed to IV
contrast material. Moreover, two studies [20,21] among
the three that used propensity matching methods used
data collected over 10 years (from 2000 to 2010) and re-
cruited 41,614 patients. Interestingly, these studies have
produced inconsistent results: one reported IV contrast
material as being positively associated with AKI, while the
other reported no significant association between IV con-
trast and AKI.
We believe that to include these more recent studies
in a new systematic review will improve the validity of avail-
able evidence on the association between IV contrast and
AKI. In particular, we will have much larger sample size
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proved in these recent studies.
Finally, since it is essential to provide clinicians with
the best available evidence on the causal association be-
tween IV contrast and AKI, the results of this systematic
review will be helpful in making evidence-based recom-
mendations and guidelines for clinical and radiologic
settings.
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